Akers Biosciences, Inc. Distribution Agreements (9126J)
April 13 2015 - 2:00AM
UK Regulatory
TIDMAKR
RNS Number : 9126J
Akers Biosciences, Inc.
13 April 2015
Embargoed: 0700hrs 13 April 2015
Akers Biosciences, Inc.
Distribution Agreements
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers" or
the "Company"), a medical device company focused on reducing the
cost of healthcare through faster, easier diagnostics, has added
six new distributors to market its rapid tests for heparin--induced
thrombocytopenia ("HIT") in nine additional countries within
Europe, the Middle East and Africa (EMEA).
The Company has signed multi-year distribution agreements for
PIFA Heparin/PF4 Rapid Assay products with Pathway Diagnostics Ltd,
covering Great Britain; ACCUSCIENCE Ireland Ltd, covering Ireland
and Northern Ireland; Tokra Medikal Tic Ltd Sti, covering Turkey;
LabPro d.o.o, covering Serbia, Montenegro, Macedonia, Bosnia and
Herzegovina; AVL Sofia Ltd, covering Bulgaria; and MASTERLAB SARL,
covering Morocco.
Akers has developed the only U.S. and E.U. cleared rapid test to
detect a potentially fatal allergy to the widely used blood
thinner, heparin. This clinical syndrome known as HIT reverses
heparin's intended therapeutic effect and transforms it into a
clotting agent. Patients suffering HIT are at risk of developing
limb- and life-threatening complications, so the rapid diagnosis
provided by the Company's Heparin/PF4 devices is paramount to
effective, clinical decision making. Millions of patients are
exposed to heparin around the world each year and between 1% and 5%
of those patients receive a HIT diagnosis. The largest at-risk
populations are patients undergoing major cardiac or orthopedic
surgical procedures.
"As sales of our rapid tests for HIT continue to rise in the
U.S. we are actively seeking to roll out the marketing to other
countries around the world," said Raymond F. Akers, Jr. PhD,
Co-founder and Executive Chairman of the Board. "These additional
distribution partnerships add to our expanding global footprint
which now exposes the Company's flagship test to 20 non-U.S.
markets including China," continued Dr. Akers.
"Key to growing the international footprint is partnering with
distributors with the right networks and experience to drive sales
- in some cases in countries where there is no established
procedure for testing for HIT," added Nicolas Daurel, Vice
President, Sales and Marketing for EMEA. "We are confident that our
international partners have these credentials and look forward to
supporting their strategies."
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRIMMITMBBBBMA
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024